Evidence map›Paper›PMID 29980517›Full record

ArticleCancer prevention research (Philadelphia, Pa.)2018

The Ashitaba (

Tianshun Zhang, Qiushi Wang, Mangaladoss Fredimoses, Ge Gao, Keke Wang, Hanyong Chen, Ting Wang, Naomi Oi, Tatyana A Zykova, Kanamata Reddy and 9 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer prevention research (Philadelphia, Pa.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Pharmaceuticals (Basel, Switzerland) · 2023
    Article
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 3 countries.

Tianshun Zhang *The Hormel Institute, University of Minnesota, Austin, Minnesota.
Qiushi WangThe Hormel Institute, University of Minnesota, Austin, Minnesota.
Mangaladoss FredimosesThe China-US (Henan) Hormel Cancer Institute, Zhengzhou, Henan, China.
Ge GaoThe Hormel Institute, University of Minnesota, Austin, Minnesota.
Keke WangThe Hormel Institute, University of Minnesota, Austin, Minnesota.
Hanyong ChenThe Hormel Institute, University of Minnesota, Austin, Minnesota.
Ting Wang *The Hormel Institute, University of Minnesota, Austin, Minnesota.
Naomi OiThe Hormel Institute, University of Minnesota, Austin, Minnesota.
Tatyana A ZykovaThe Hormel Institute, University of Minnesota, Austin, Minnesota.
Kanamata ReddyThe Hormel Institute, University of Minnesota, Austin, Minnesota.
Ke YaoThe Hormel Institute, University of Minnesota, Austin, Minnesota.
Weiya MaThe Hormel Institute, University of Minnesota, Austin, Minnesota.
Xiaoyu ChangThe Hormel Institute, University of Minnesota, Austin, Minnesota.
Mee-Hyun LeeThe China-US (Henan) Hormel Cancer Institute, Zhengzhou, Henan, China.
Moeez Ghani RathoreThe Hormel Institute, University of Minnesota, Austin, Minnesota.
Ann M BodeThe Hormel Institute, University of Minnesota, Austin, Minnesota.
Hitoshi AshidaDepartment of Agrobioscience, Graduate School of Agricultural Science, Kobe University, Nada-ku, Kobe, Japan.
Scott M LippmanUniversity of California San Diego Health Science. slippman@ucsd.edu zgdong@hi.umn.edu.
Zigang DongThe Hormel Institute, University of Minnesota, Austin, Minnesota. slippman@ucsd.edu zgdong@hi.umn.edu.
Hormel (United States) · USChina-US (Henan) Hormel Cancer Institute · CNKobe University · JPUniversity of San Diego · US

Funding

Chemoprevention of colon cancer by targeting the Wnt/beta-catenin pathwayR01CA187027 · NCI · UNIVERSITY OF MINNESOTA · PI KANG, NINGLING, ROH, EUNMIRI · 2015 to 2019
$1.7M
Prevention of solar UV-induced skin cancer by targeting LTA4HR01CA196639 · NCI · UNIVERSITY OF MINNESOTA · PI LIU, LIANG · 2015 to 2019
$1.7M
Developing new ornithine decarboxylase inhibitors to prevent skin & colon cancerR01CA166011 · NCI · UNIVERSITY OF MINNESOTA · PI DONG, ZIGANG · 2013 to 2017
$1.6M
NCI NIH HHS R01 CA166011NCI NIH HHS R01 CA187027NCI NIH HHS R01 CA196639
6 · The paper itself

Abstract

Malignant melanoma is an aggressive tumor of the skin and still lacks effective preventive and therapeutic treatments. In melanoma, both the BRAF/MEK/ERK and PI3-K/AKT signaling pathways are constitutively activated through multiple mechanisms, which result in cell-cycle progression and prevention of apoptosis. Therefore, the development of novel strategies for targeting BRAF and PI3K are of utmost importance. In this study, we found that Ashitaba (

Indexed as

AngelicaAnimalsCarcinogenesisCell Line, TumorChalconeDrug Screening Assays, AntitumorHumansMelanoma, ExperimentalMiceMice, KnockoutMutationPhosphatidylinositol 3-KinasesPlant ExtractsProto-Oncogene Proteins B-rafPTEN PhosphohydrolaseSignal Transduction4-hydroxyderricinBraf protein, mouseChalconePhosphatidylinositol 3-KinasesPlant ExtractsProto-Oncogene Proteins B-rafPTEN PhosphohydrolasePten protein, mousexanthoangelol

Identifiers

PMID29980517
PMCPMC6317334
OpenAlexW2856393804

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.